Vaccine Choice Canada

Your Child. Your Future. Your Choice.

Donate Button
  • About Vaccines
    • Vaccination: Basic Concerns
      • Children’s Health in Decline
      • Contraindications to Vaccination
      • Parent’s Guide to Vaccination
      • Adverse Events – Unreported
      • Disease Trends
    • General Issues
      • Informed Consent – Mature Minor – Ethics
      • Politics of Vaccination
      • Healthcare Worker & Student Vaccines
      • Herd Immunity
      • Doctors Speak
      • Parents Speak
      • Reports
    • Specific Vaccines
    • Vaccine Ingredients
  • Health Risks
  • Science
  • Exemptions
    • Legal Exemption Forms
    • Canadian Medical Law
    • Ontario Daycare Exemptions
    • Immunization Not Mandatory in Canada
    • Threats to Exemptions
    • Take Action / Events
  • Personal Stories
  • Alternatives
    • Alternatives – Specific Infections
  • Articles
  • Resources
    • Child Health Links
    • Pro-vaccine websites
    • Video & Audio
  • Home
  • About VCC
    • Policy Statement on Vaccination
    • Who We Are & What We Do
    • VCC History
    • Privacy Policy
    • Disclaimer
  • Join
  • Report a Reaction
  • Bookstore
  • Contact
  • Member’s Area
    • Journal Archive
  • Site Map
  • Media
You are here: Home / About Vaccines / Adverse Events / FluMist live virus influenza vaccine – best to hold your nose?

FluMist live virus influenza vaccine – best to hold your nose?

November 19, 2012 By Vaccine Choice Canada

FluMist® live virus nasal spray vaccine was licensed in 2010 for use by Canadians 2-59 yrs old. Health Canada’s licensing information about it’s manufacture tells us (section 3.1.1. General Information) that wild-type influenza viruses are first cultured in eggs, then genetically engineered to produce the FluMist® viruses which have combined properties of wild-type virus and lab-altered, cold-adapted virus. The cold-adaption allows the virus to replicate efficiently at 25°C, a temperature common to the nasopharynx but too low to allow efficient replication of wild-type influenza A and B (which prefer temperatures of 39°C and 37°C respectively, common to the lungs). The expected outcome is, “a protective immune response without causing clinical disease.”

But despite this, the evidence provided in Table 1, pgs 6-7 of the AstraZeneca FLUMIST® monograph indicates dubious effectiveness. Adverse reactions of children 2-17 yrs old included: runny/stuffy noses (64%), coughs (40%), headaches (13%), fever (11%), and muscle aches (8%) – all the symptoms of influenza and influenza-like illness (ILI).
(Note that parents of young children might be confused by evidence found by Osterholm et al published in their 2012 University of Minnesota analysis that live virus influenza vaccine (LAIV) has relatively high efficacy in babies and children 6 months to 7 years of age. But, as the authors explain on page 21, efficacy is only a measure of antibody response found in vaccine trials and isn’t the same as effectiveness in the real world.)

Adults especially, might be interested in an article titled, ‘Important Safety Information’ [no longer on the Internet, but can be viewed here] on AstraZeneca’s FlumistCanada website for healthcare professionals. Stated in the last paragraph (and duplicated on page 4 of their monograph), is the warning: “If Guillain-Barré syndrome occurred within 6 weeks of any prior influenza vaccination or if an individual is immunosuppressed, the decision to give FluMist® should be based on careful consideration of the potential benefits and risk.” VRAN hopes that individuals who’ve suffered from Guillain-Barré syndrome following influenza vaccination would recall the incompetence of influenza vaccines and err on the side of caution, no matter how willing a healthcare professional is to ignore the potential for an adverse reaction and administer the vaccine.

The 2011 statement by the National Advisory Committee on Immunization (NACI) concerning LAIV recommends that, “TIV [trivalent injected influenza vaccine], instead of LAIV, should be used for healthcare workers providing care to individuals with immune compromising conditions, unless the healthcare worker will only accept LAIV. If a healthcare worker or other person receives LAIV and is providing care to individuals with severe immune compromising conditions (defined as hospitalized and requiring care in a protected environment), they should wait two weeks following receipt of LAIV before continuing to provide care to such individuals.” (Note that FluMist® is a more expensive vaccine than the recommended injected vaccine.) Adding the obvious, NACI warns that furthermore, “FluMist® should not be administered to persons with immune compromising conditions, due to underlying disease and/or therapy” explaining that, “Studies on FluMist® have shown that vaccine virus can be recovered by nasal swab in children and adults following vaccination (i.e. ‘shedding’).” Related to this are the monograph warnings: “FLUMIST should be given to pregnant women only if clearly needed.” and, “It’s not known whether FLUMIST is excreted in human milk…caution should be exercised if FLUMIST is administered to nursing mothers.” Considering how poorly effective FluMist® and other influenza vaccines are, why would any of them be “clearly needed”, especially for pregnant women. And how cautious is it to go ahead and vaccinate a nursing mother without having any information about possible risk to her nursing child?

The NACI has much to say about the use of LAIV in children with asthma and, again, waffles about the need for restrictions. It states: “NACI recommends that LAIV can be used in children 24 months and older with stable, nonsevere asthma and in children with chronic health conditions (excluding those with immune compromising conditions and severe asthma).” It feebly continues, “Based on expert review, it is expected that LAIV should be as safe, immunogenic and efficacious in immune competent children with chronic health conditions as it is in healthy children. At this time there is insufficient evidence available to prefer LAIV over TIV in children with chronic health conditions.” It struggles: “LAIV is not recommended for children with immune compromising conditions or those with severe asthma (as defined as currently on oral or high dose inhaled glucocorticosteriods or active wheezing) or those with medically-attended wheezing in the 7 days prior to vaccination, but can be given to children with stable, non-severe asthma.” (Note that an analysis of a 2003 Canadian health survey found 80% more asthma flare-ups in flu shot recipients and a 2012 study from Mayo Clinic found flu shots provided no protection against hospitalization of children, especially those with asthma. In fact, it found a threefold increased risk of hospitalization for children who’d received flu shots. If a killed virus influenza vaccine can do this, what is a live virus one such as FluMist® likely to do?)

Noting some of the questionable ingredients, page 4 of the FluMist® monograph warns: “FLUMIST® is contraindicated in individuals with a history, especially anaphylactic reactions, to eggs, egg proteins, gentamicin, gelatin, or arginine or to any other ingredients.” Considering the close proximity of the nasal cavities to the brain and the incomplete blood/brain barrier of children younger than 2-3 yrs old, the excitotoxin, MSG, is another ingredient which should cause concern. As well as Guillaine-Barré Syndrome and anaphylaxis, pg 10 of the monograph lists other serious reactions reported post-marketing: Bell’s Palsy (temporary or permanent paralysis of the facial nerve which may cause an inability to open an eye or close the mouth), facial swelling, nosebleed, hives and rash. And, as is usual for vaccines, there’s the statement (pg 20): “FLUMIST has not been evaluated for its carcinogenicity or mutagenic potential or its potential to impair fertility.”

Whereas vaccination with FluMist® alone is obviously not without risks, what are the risks of receiving other drugs/vaccines at the same time? Table 3 on pg 11 of the monograph notes that, due to a risk of Reye’s Syndrome, concurrent administration with aspirin should be avoided in those under 18 yrs and aspirin should be avoided until 5 weeks following vaccination. However, trials studying concurrent administration of FluMist® and measles, mumps, rubella and varicella (chickenpox) vaccines found, “Adverse events were similar to those seen in other clinical studies with FLUMIST.” – not inspiring results and dubious, considering the studies were examining concurrent administration of a total of six to seven types of living viruses which might be able to recombine within children’s bodies into new, more infectious pathogens.

Finally, for vaccine administrators and taxpayers who fund “free” vaccines, packaging and storage is an issue. Page 13 of the monograph tells us that FluMist® is supplied in pre-filled single-use glass sprayers which must be stored “in a refrigerator (2°C-8°C) upon receipt and until use. DO NOT FREEZE. Use the product as indicated by the expiration date on the sprayer label.” At the beginning of the influenza season in 2012, Albertans were informed that “free” FluMist® which had been purchased for 2-17 yr olds was being made available to anyone 2-59 yrs eligible and willing to receive it. Chief MOH, Dr James Talbot explained that, by early November, only 25% of the FluMist® taxpayers had funded had been accepted and that LAIV has a shorter shelf life than TIV.

Share this:

Filed Under: Adverse Events, Anaphylaxis, Allergies, and Asthma, Biological Ingredients, Influenza Vaccine, Specific Vaccines Tagged With: flu shot, Influenza Vaccine, live virus vaccine

Articles by Category

  • About Vaccines
    (179)
    • Adverse Events
      (106)
    • Compensation
      (6)
    • Contraindications
      (1)
    • Herd Immunity
      (11)
    • Informed Consent – Mature Minor – Ethics
      (80)
    • Reports
      (13)
  • Disease Trends
    (27)
  • Doctors Speak
    (54)
  • Exemptions
    (171)
    • Take Action
      (111)
    • Threats to Exemptions
      (153)
  • Health Risks
    (147)
    • Anaphylaxis, Allergies, and Asthma
      (26)
    • Autism
      (55)
    • Brain and Neurological Injuries
      (37)
    • Cancer
      (3)
    • Decline in Children's Health
      (26)
    • Gulf War Syndrome
      (4)
    • Infertility
      (1)
    • Obesity and Diabetes
      (4)
    • Pregnancy – Risks to the Foetus
      (5)
    • SIDS-SBS
      (12)
  • Media
    (83)
  • Parents Speak
    (32)
  • Personal Stories
    (28)
  • Politics of Vaccination
    (40)
  • Resources
    (61)
    • Books & Periodicals
      (1)
    • PDF files
      (3)
    • Videos
      (0)
  • Specific Vaccines
    (228)
    • Chickenpox and Shingles Vaccines
      (12)
    • COVID-19 Vaccine
      (10)
    • Diphtheria, Tetanus, Pertussis, and Hib Vaccine
      (38)
    • Healthcare Worker & Student Vaccines
      (15)
    • Hepatitis-B Vaccine
      (20)
    • HPV Vaccine
      (19)
    • Influenza Vaccine
      (46)
    • Measles, Mumps, & Rubella Vaccine
      (47)
    • Meningococcal Disease Vaccine
      (9)
    • Pet Vaccines
      (1)
    • Pneumococcal Disease Vaccine
      (4)
    • Polio Vaccine
      (13)
    • Rotavirus Vaccine
      (1)
    • Smallpox Vaccine
      (4)
    • Travel Vaccines
      (1)
  • Vaccine Alternatives
    (13)
    • Vaccine Alternatives – General
      (7)
    • Vaccine Alternatives – Specific Infections
      (6)
  • Vaccine Ingredients
    (69)
    • Aluminum
      (23)
    • Biological Ingredients
      (15)
    • Chemical Ingredients
      (15)
    • Food Allergens
      (4)
    • Mercury
      (24)
    • Oil-based Adjuvants
      (11)

Join Vaccine Choice Canada

To support our educational and outreach work , please join Vaccine Choice Canada today. Sign Me Up!

Log In


Lost your password?

About Vaccine Choice Canada

Vaccine Choice Canada is a volunteer run, federally registered … read more

Our Mission

Vaccine Choice Canada (formerly VRAN) continues the work of … more

Disclaimer

The contents of this website are for informational purposes … more

Vaccine Choice Canada logo

Find More on

  • Decline in Children's Health
    (26)
  • Doctors Speak
    (54)
  • Exemptions
    (130)
  • Health Risks
    (39)
  • Parents Speak
    (32)
  • Personal Stories
    (28)
  • Resources
    (60)
  • Specific Vaccines
    (92)
  • Vaccine Alternatives
    (8)
  • Vaccine Ingredients
    (22)

Personal Stories

Susan’s Flu Vaccine Reaction

In 2013, I contracted the H1N1 strain of flu.  I was deathly … [Read More...]

My Journey with Vaccine Awareness and a closer look at Vaxxed vs. Unvaxxed

I was born in the mid 1980’s and was fully vaccinated as a … [Read More...]

A story of my grandson’s visit, discovery of his autism, and how he recovered

By Shanna Mi    November 2019 It was a glorious late … [Read More...]

Laura’s Story

July 2002 Today is my daughter's sweet 16th birthday but … [Read More...]

More Personal Stories

Featured Articles

News Nuggets April 12, 2021 – Top News Items

Compiled by Edda West FEATURES Perspectives on the … [Read More...]

COVID-19

COVID-19 Resources (printable) & Take Action – Letter … [Read More...]

News Nuggets April 2, 2021 – Top News Items

Compiled by Edda West FEATURES Naomi Wolf speaks to … [Read More...]

News Nuggets March 26, 2021- Top News Items

Compiled by Edda West FEATURES Vera Sharav - Holocaust … [Read More...]

More News Articles

Copyright © 2021 Vaccine Choice Canada